S-1: Entero Therapeutics Files for $6 Million Offering to Advance Adrulipase Program

Entero Therapeutics seeks to raise capital through a common stock and pre-funded warrant offering to fund the development of its lead drug candidate, Adrulipase, and manage existing liabilities.

Summary

• Entero Therapeutics has filed a Form S-1 registration statement for a proposed offering of 16,666,667 shares of common stock and pre-funded warrants to purchase an additional 16,666,667 shares.
• The estimated public offering price is $0.36 per share, based on the sale price of the common stock on Nasdaq on May 2, 2025.
• The company intends to use the net proceeds to advance the development of Adrulipase, its lead product candidate, and for general corporate purposes, including repayment of certain outstanding liabilities.
• A portion of the proceeds, up to $1.5 million, is allocated for marketing and advertising services.
• The company anticipates needing additional capital by the end of the third quarter of 2025 to fund Phase 3 clinical trials for Adrulipase.
• Entero Therapeutics recently underwent a merger with ImmunogenX, Inc., but is now pursuing a rescission agreement to unwind the merger and focus on Adrulipase.
• The company has a history of net losses and a going concern qualification in its audits for the financial years ended December 31, 2024 and 2023.
• As of December 31, 2024, Entero Therapeutics had approximately $0.2 million in cash and cash equivalents and an accumulated deficit of approximately $202.4 million.
• The number of full-time employees was reduced from 15 as of March 31, 2024 to two (2) as of May 9, 2025, with the headcount reduction arising as a result of significant capital constraints faced by the Company.

Sentiment

Score: 4

Explanation: The sentiment is neutral to slightly negative. While the company is pursuing a strategic refocus and has a lead drug candidate, it faces significant financial challenges and uncertainties about its future.

Positives

• The offering aims to provide funding for the Adrulipase program, which has shown promising results in Phase 2 clinical trials.
• The rescission of the ImmunogenX merger could streamline operations and reduce debt obligations.
• The company has a clear plan to seek follow-on financing for Phase 3 trials of Adrulipase.
• The company has a revolving loan agreement in the principal amount of $2.0 million.

Negatives

• The company has a history of net losses and a significant accumulated deficit.
• There is a going concern qualification in the company's audits.
• The company is dependent on external funding to continue operations.
• The company's stock price is low, leading to substantial dilution for new investors.
• The company faces the risk of delisting from Nasdaq if it cannot maintain compliance with listing requirements.
• The number of full-time employees was reduced from 15 as of March 31, 2024 to two (2) as of May 9, 2025, with the headcount reduction arising as a result of significant capital constraints faced by the Company.

Risks

• The company's dependency on external funding raises substantial doubt about its ability to continue as a going concern.
• Failure to consummate the transactions contemplated under the Rescission Agreement may have an adverse effect on the company's business, financial condition and results of operations.
• The company may be unable to achieve or sustain profitability in the future.
• The company's management has broad discretion over the use of the net proceeds from the offering.
• The company will require additional financing to advance the development of Adrulipase, which may not be available on acceptable terms, or at all.
• Future sales of the company's common stock could lower its stock price and dilute existing stockholders.
• The company's failure to maintain compliance with Nasdaq's continued listing requirements could result in the delisting of shares of its Common Stock.
• If shares of the company's common stock become subject to the penny stock rules, it would become more difficult to trade the company's shares.

Future Outlook

The company plans to advance the Adrulipase program and seek follow-on financing by the end of the third quarter of 2025 to fund Phase 3 clinical trials.

Management Comments

• The Companys decision to pursue a rescission agreement with ImmunogenX, LLC was driven by the strategic imperative to concentrate limited financial and operational resources on Adrulipase, the Companys primary drug candidate.
• The Company believes this strategic refocusing is supported by multiple business and financial considerations.

Industry Context

The document does not provide specific details on how this announcement relates to broader industry trends or competitors beyond mentioning the PERT market size and growth.

Comparison to Industry Standards

• The PERT market is well established with estimated sales of approximately $2.1 billion in 2024 in the U.S. and has been growing for the past five years at a compound annual growth rate of approximately 20%.

Management Changes

Legal Proceedings

• Mattress Liquidators, Inc. filed a complaint against ImmunogenX, LLC, Jack A. Syage, and The Jack A. Syage and Elizabeth T. Syage Revocable Trust on December 31, 2024, alleging breach of a credit agreement.
• Effective April 9. 2025, and executed May 8, 2025, Plaintiff and Defendants entered into a settlement agreement (Settlement Agreement) whereby Jack A. Syage and The Jack A. Syage and Elizabeth T. Syage Revocable Trust (the Guarantors) agreed to pay the Plaintiff (a) $5,500,000.00 to be applied to the obligations amounting to approximately $7.9 million owed to the Plaintiff (which amount was paid to the Plaintiff on April 9, 2025) with the Guarantors being solely responsible for payment of all obligations due to be paid to the Plaintiff.
• Ellenoff Grossman & Schole LLP filed a lawsuit against the company on March 17, 2025, seeking to recover unpaid legal fees, costs, and disbursements amounting to $749,301.00.

Stakeholder Impact

• Shareholders face potential dilution from the offering and risks related to the company's financial condition.
• Employees have experienced headcount reductions due to capital constraints.
• The company's ability to develop and commercialize Adrulipase could impact patients with EPI.

Next Steps

• The company intends to use the net proceeds from this offering to advance the Adrulipase program.
• The company plans to seek follow-on financing by the end of the third quarter of 2025 to fund Phase 3 clinical trials.
• The company expects that the closing of the Rescission Agreement will occur on or prior to June 30, 2025, subject to satisfaction of all conditions for closing, including obtaining shareholder approval by the Company for the transfer of the Membership Interests to the IMGX Shareholders.
• The company is planning to move this program forward in 2025 including with the intent to initiate a Ph2b clinical trial in the second half of 2025.

Key Dates

Keywords

Adrulipase, offering, pre-funded warrants, ImmunogenX, rescission, clinical trials, EPI, cystic fibrosis, financing, biopharma